{"id":11044,"date":"2014-01-30T00:00:00","date_gmt":"2014-01-29T23:00:00","guid":{"rendered":"https:\/\/idibell.cat\/es\/blog\/2014\/01\/30\/descubren-una-marca-epigenetica-que-podria-ser-util-para-la-clasificacion-del-origen-de-la-leucemia-y-la-recaida-de-la-enfermedad\/"},"modified":"2020-05-22T09:44:12","modified_gmt":"2020-05-22T07:44:12","slug":"descubren-una-marca-epigenetica-que-podria-ser-util-para-la-clasificacion-del-origen-de-la-leucemia-y-la-recaida-de-la-enfermedad","status":"publish","type":"post","link":"https:\/\/idibell.cat\/es\/2014\/01\/descubren-una-marca-epigenetica-que-podria-ser-util-para-la-clasificacion-del-origen-de-la-leucemia-y-la-recaida-de-la-enfermedad\/","title":{"rendered":"Descubren una marca epigen\u00e9tica que podr\u00eda ser \u00fatil para la clasificaci\u00f3n del origen de la leucemia y la reca\u00edda de la enfermedad"},"content":{"rendered":"
Un estudio internacional entre el grupo de Impresi\u00f3n Gen\u00f3mica del Programa de Epig\u00e9tica y Biolog\u00eda del C\u00e1ncer del IDIBELL y la Universidad Christian-Albrechts de Kiel, Alemania, describe una firma de metilaci\u00f3n como un prometedor marcador para la clasificaci\u00f3n de las leucemias mieloides derivadas.
El gen del tumor de Wilms 1 (WT1) est\u00e1 sobreexpresado en numerosos tipos de c\u00e1ncer con respecto a las c\u00e9lulas normales, y tiene una funci\u00f3n oncog\u00e9nica o de supresor de tumores dependiendo del contexto celular.
El estudio publicado en la Revista Hematology and Oncology (Guiliaumet – Adkins et al., 2014) revel\u00f3 que a pesar de la alta expresi\u00f3n de WT1 en l\u00edneas celulares derivadas de Leucemia mieloide aguda (LMA),
existe un interruptor epigen\u00e9tico que pasa de la forma permisiva a la represiva de la cromatina. El an\u00e1lisis de metilaci\u00f3n en 356 muestras de leucemia y linfoma primario
revela que la firma epigen\u00e9tica identificada en l\u00edneas celulares es espec\u00edfica de linajes malignos, independientemente del estado mutacional subyacente o translocaci\u00f3n.
David Monk explic\u00f3 que \u00abhemos demostrado que la firma epigen\u00e9tica AWT1 es un excelente marcador para discriminar la LMA de sangre perif\u00e9rica no enferma y que esta firma puede rastrear con precisi\u00f3n la progresi\u00f3n de la enfermedad, diferenciando pacientes que han reca\u00eddo de los que lograron la remisi\u00f3n completa despu\u00e9s del trasplante alog\u00e9nico de c\u00e9lulas madre hematopoy\u00e9ticas (SCT )\u201d.
La hipermetilaci\u00f3n del promotor AWT1 alternativa en neoplasias hematol\u00f3gicas es un marcador altamente espec\u00edfico para las leucemias mieloides agudas pesar de los niveles elevados de expresi\u00f3n . Guillaumet – Adkins A, J Richter , Odero MD, Sandoval J, Agirre X, Catala A, Esteller M , Pr\u00f3sper F , Calasanz MJ , Bu\u00f1o I, Kwon M , Corte F , R Siebert , Monk D. J Hematol Oncol . 2014 09 de enero, 7(1):4.<\/p>\n","protected":false},"excerpt":{"rendered":"
Un estudio internacional entre el grupo de Impresi\u00f3n Gen\u00f3mica del Programa de Epig\u00e9tica y Biolog\u00eda del C\u00e1ncer del IDIBELL y la Universidad Christian-Albrechts de Kiel, Alemania, describe una firma de metilaci\u00f3n como un prometedor marcador para la clasificaci\u00f3n de las leucemias mieloides derivadas. El gen del tumor de Wilms 1 (WT1) est\u00e1 sobreexpresado en numerosos […]<\/p>\n","protected":false},"author":6,"featured_media":11045,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"no-sidebar","site-content-layout":"page-builder","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[184,286],"tags":[],"class_list":["post-11044","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-area-cancer","category-epigenetica-del-cancer-cancer"],"publishpress_future_action":{"enabled":false,"date":"2024-12-26 00:51:33","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/posts\/11044","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/comments?post=11044"}],"version-history":[{"count":0,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/posts\/11044\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/media\/11045"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/media?parent=11044"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/categories?post=11044"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/tags?post=11044"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}